Ratings by H.C. Wainwright (Mitchel Kapoor)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/8/2026 | MeiraGTx Holdings plc | MGTX | Maintain | Buy (Buy) |
|
Details | ||
| 6/30/2026 | Neurogene | NGNE | Maintain | Buy (Buy) |
|
Details | ||
| 6/9/2026 | Neurogene | NGNE | Maintain | Buy (Buy) |
|
Details | ||
| 5/26/2026 | MeiraGTx Holdings plc | MGTX | Maintain | Buy (Buy) |
|
Details | ||
| 5/14/2026 | Avalo Therapeutics Inc. | AVTX | Maintain | Buy (N/A) |
|
Details | ||
| 4/20/2026 | MeiraGTx Holdings plc | MGTX | Maintain | Buy (Buy) |
|
Details | ||
| 3/26/2026 | Neurogene | NGNE | Maintain | Buy (Buy) |
|
Details | ||
| 3/25/2026 | Avalo Therapeutics Inc. | AVTX | Maintain | Buy (N/A) |
|
Details | ||
| 1/15/2026 | Avalo Therapeutics Inc. | AVTX | Maintain | Buy (Buy) |
|
Details | ||
| 11/24/2025 | MeiraGTx Holdings plc | MGTX | New Coverage | Buy (N/A) |
7.46 (12.34) |
65.42% | Details | |
| 11/13/2025 | Neurogene | NGNE | Maintain | Buy (N/A) |
|
Details | ||
| 10/24/2025 | Boundless Bio Inc. | BOLD | Maintain | Buy (Buy) |
|
Details | ||
| 10/3/2025 | Neurogene | NGNE | Maintain | Buy (Buy) |
|
Details | ||
| 9/18/2025 | Avalo Therapeutics Inc. | AVTX | Maintain | Buy (N/A) |
|
Details | ||
| 8/11/2025 | Boundless Bio Inc. | BOLD | Maintain | Buy (N/A) |
|
Details | ||
| 6/2/2025 | Boundless Bio Inc. | BOLD | New Coverage | Buy (N/A) |
1.10 (2.44) |
121.82% | Details | |
| 6/2/2025 | Avalo Therapeutics Inc. | AVTX | New Coverage | Buy (N/A) |
4.00 (18.91) |
372.75% | Details | |
| 3/25/2025 | Neurogene | NGNE | Maintain | Buy (N/A) |
|
Details | ||
| 11/25/2024 | Neurogene | NGNE | Maintain | Buy (Buy) |
|
Details | ||
| 11/12/2024 | Neurogene | NGNE | Maintain | Buy (N/A) |
|
Details | ||
| 8/12/2024 | Neurogene | NGNE | Maintain | Buy (N/A) |
|
Details | ||
| 5/13/2024 | Neurogene | NGNE | Maintain | Buy (N/A) |
|
Details | ||
| 3/19/2024 | Neurogene | NGNE | Maintain | Buy (N/A) |
|
Details | ||
| 1/8/2024 | Neurogene | NGNE | New Coverage | Buy (N/A) |
22.95 (38.32) |
66.97% | Details |
